شركة بني خطيرة والعادة أنا لا احبذ هذه الشركات إلا في نطاق ضيق جدا كأن تكون الشركة جيدة أساسيا و عند دعم ومستقرة سعريا في نطاق معين أو في بداية رالي .. هذه الشركة كانت في النازداك وخرجت بكرت أحمر .. لاحظت فقط أن عليها توصية من بيتر ليدز أمس وكتب عنها كلام جيد وقال انها في مناطق شراء مغرية وأعطاها هدف على المدى البعيد $1.40 - $1.85 وأنا انقل كلامه وتشارته بدون تعليق .. أغلاق امس 0.495 CardioGenesis Corp CGCP (OTC-BB) Industry: Medical Equipment and Supplies Price as of October 7 - $0.47 Long-term Target - $1.40 - $1.85 CGCP will leave a hole in your heart and not feel a pang of guilt. CGCP develops and distributes laser-based surgical products and disposable fiber-optic accessories for the treatment of advanced cardiovascular disease through transmyocardial revascularization (TMR) and percutaneous transluminal myocardial revascularization (PMR) TMR market leader with greater than 70% market share TMR and PMR are laser-based heart treatments that channel through the heart muscle into the heart chamber to help circulation in cardiac patients. CGCP’s TMR 2000 system has been approved for sale in the U.S by the FDA. The only company that produces laser devices for the PMR procedure, CGCP’s Axcis PMR is currently being marketed in Europe and other international markets. Nearly 50% of the nation's top 500 cardiac centers utilize the TMR 2000 Financially, CGCP is on very solid ground. The company’s second quarter revenues were up 9% at $3.4 million, while its net loss decreased significantly, falling from $878,000 in 2003 to $264,000 in 2004. Year-to-date, CGCP’s revenues were up 14% at $7.4 million. Net income for the first half of 2004 was $3,000; this compares to a net loss of $757,000 in the prior year period. It’s also important to note that CGCP’s balance sheet showed cash and cash equivalents of $3.1 million, shareholders equity of $6.4 million, and no long-term debt. The company’s R&D department is also busy with the FDA regarding PMR. CGCP and the FDA recently agreed on the steps needed to design and initiate a new clinical trial to confirm the safety and efficacy of PMR for use in the U.S. This agreement now opens the door for CGCP to quickly formalize a clinical protocol and begin the definitive trial of PMR. CGCP also has a strong portfolio of intellectual properties related to devices and applications in the growing field of angiogenesis (the growth of abnormal blood vessels). They have over 90 U.S. and International patents or patent applications issued to date. Plus more than 75 U.S. and International patent applications are pending.